Home » Care » Highlight the breadth of research propelling developments in clinical cardiology.

Feldman stated. ‘The EVEREST II study will take the next step, assigning sufferers to MitraClip therapy or surgery treatment randomly.’ Dr. Feldman will present this study on Monday, March 26, at 1:30 p.m. In La Nouvelle Orleans C. Experts in the RegEx research are also evaluating whether incorporating mild exercise into the scan protocol further boosts image quality. ‘In nuclear cardiology, pictures are everything,’ said Dr. Gregory Thomas, a scientific associate professor of medication at the University of California Irvine and director of nuclear cardiology at Objective Internal Medical Group, Mission Viejo, CA.The acquisition provides Abbott with a presence in the growing area of nonsurgical treatment for structural heart disease. Announced Acquisition of Visiogen, Inc.: Announced an contract to acquire Visiogen, Inc., offering the business with a next-era accommodating intraocular lens technology to address presbyopia for cataract patients. Received Approval for Bloodstream Screening Ensure that you Launched a fresh Diagnostic Instrument: Received approval from the U.S. Food and Drug Administration for ABBOTT PRISM HIV O Plus test, the first automated blood screening test for HIV-1/HIV-2 fully.